| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Department of Clinical Pharmacology, University of Dundee, Scotland
We have studied the hemodynamic and hormonal effects of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in eight patients with cor pulmonale. Subjects were studied twice and were given a 20-min placebo infusion followed by either ANP or BNP (3 pmol/kg/min then 10 pmol/kg/min for 20 min each). Responses were measured after placebo infusion and following low-dose then high-dose ANP or BNP. Placebo infusion had no significant effects on either study day. Low-dose ANP and BNP significantly reduced mean pulmonary artery pressure (MPAP) from baseline by 3.7 mm Hg (95% confidence interval [CI], 1.4 to 6.1) and 3.0 mm Hg (95% CI, 0.6 to 5.4), respectively. High-dose ANP and BNP further reduced MPAP from baseline by 7.1 mm Hg (95% CI, 4.8 to 9.4) and 7.1 mm Hg (95% CI, 4.7 to 9.6), respectively. Effects on total pulmonary vascular resistance were similar. ANP and BNP had no confounding systemic hemodynamic effects. Plasma aldosterone was significantly suppressed from baseline by ANP: 156 pmol/L (95% CI, 93 to 220) after low dose, 275 pmol/L (95% CI, 207 to 343) after high dose; and by BNP: 92 pmol/L (95% CI, 30 to 153) after low dose, 159 pmol/L (95% CI, 98 to 220) after high dose. ANP and BNP produced dose-related pulmonary vasodilatation in patients with cor pulmonale, without worsening oxygen saturation or affecting systemic hemodynamics. ANP and BNP also exerted favorable neurohormonal effects by suppressing aldosterone.
Key Words: atrial natriuretic peptide • brain natriuretic peptide • cor pulmonale • pulmonary hypertension • renin-angiotensin system
Submitted on January 18, 1996
Accepted on May 2, 2007
This article has been cited by other articles:
|
|
 |
|
  J. R. Klinger, S. Thaker, J. Houtchens, I. R. Preston, N. S. Hill, and H. W. Farber Pulmonary hemodynamic responses to brain natriuretic Peptide and sildenafil in patients with pulmonary arterial hypertension. Chest, February 1, 2006; 129(2): 417 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Witteles, K. Matsuda, and M. B. Fowler B-Type Natriuretic Peptide Is Effective Therapy before Care Ann Intern Med, December 7, 2004; 141(11): 895 - 895. [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, and J. Behr Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 360 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, I. Ding, C. Neurohr, M. Vogeser, T. Kolbe, M. Schwaiblmair, and J. Behr Clinical significance of brain natriuretic peptide in primary pulmonary hypertension J. Am. Coll. Cardiol., March 3, 2004; 43(5): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Michaels, A. Klein, J. A. Madden, and K. Chatterjee Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen Uptake Circulation, June 3, 2003; 107(21): 2697 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zellner, A. A. Protter, E. Ko, M. R. Pothireddy, T. DeMarco, S. J. Hutchison, T. M. Chou, K. Chatterjee, and K. Sudhir Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1049 - H1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhao, L. Long, N. W. Morrell, and M. R. Wilkins NPR-A–Deficient Mice Show Increased Susceptibility to Hypoxia-Induced Pulmonary Hypertension Circulation, February 9, 1999; 99(5): 605 - 607. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
